Awny Samaan Botros Farajallah Sells 14,006 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Awny Samaan Botros Farajallah sold 14,006 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $239,502.60. Following the completion of the sale, the insider owned 116,177 shares in the company, valued at $1,986,626.70. The trade was a 10.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Up 1.5%

Shares of TAK stock opened at $17.64 on Friday. Takeda Pharmaceutical Co. has a twelve month low of $12.99 and a twelve month high of $18.90. The stock has a market cap of $56.53 billion, a P/E ratio of 51.89 and a beta of -0.08. The stock has a 50 day moving average of $16.57 and a 200 day moving average of $17.14. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The business had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%. As a group, sell-side analysts expect that Takeda Pharmaceutical Co. will post 0.32 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Zacks Research raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings downgraded shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Private Trust Co. NA grew its stake in Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after acquiring an additional 783 shares during the period. Parkside Financial Bank & Trust raised its position in Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after acquiring an additional 1,684 shares during the period. SHP Wealth Management purchased a new position in Takeda Pharmaceutical in the 4th quarter valued at about $42,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Takeda Pharmaceutical by 313.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after acquiring an additional 2,328 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after purchasing an additional 1,292 shares in the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.